A117(e.g. cough). The more complex concepts of 'chest heaviness' and 'chest tightness' were experienced by participants of all ages, but were rarely reported spontaneously by the younger children. ConClusions: There was consistency in the symptoms reported by children and adults but younger children were less likely to spontaneously report the more complex symptoms. Using age-appropriate language, pictograms and creative tasks can help elicit content from younger children.
mortality rates associated with stage III detection, and (2) mortality rates were stageshifted from stage IV to III, stage III to II, and stage II to I detection and assigned the associated mortality rates. Results: In a hypothetical cohort of 100,000 persons, 1,233 were estimated to be diagnosed with any cancer, of whom 414 were expected to die within 5 years. Of 229 diagnosed with metastatic cancer, 174 were expected to die within 5 years. If all metastatic cancers were diagnosed at stage III, 79 fewer cancer deaths would be expected, a reduction of 45% in the deaths due to metastatic cancer, or 19% of all cancer deaths. If all metastatic cancers were diagnosed at stage III, all stage III diagnosed at stage II, and all stage II diagnosed at stage I, 131 fewer cancer deaths would be expected, a reduction of 32%. Conclusions: Diagnosing cancer before metastasis, even at stage III, could result in substantial reductions in the overall cancer mortality rate.
and Welfare decided to extend coverage for oral hepatitis C drugs to all the patients. It is expected to eradicate the disease by 2025. The objective of this study was to assess the budget impact of introducing direct-acting antivirals (DAAs) coverage for all HCV patients from the perspective of the Taiwan health care payer. Methods: A budget impact model was developed with a five-year time horizon (2019)(2020)(2021)(2022)(2023) to estimate the long-term budget impact on the National Health Insurance after introducing DAA-based treatments (Glecaprevir/ pibrentasvir ) for all genotypes of patients with chronic HCV infection in Taiwan. We compared the new scenario with the historical situation based on the traditional therapy available prior to 2018. The eligible patient population was derived from the local published epidemiology data. Drug unit costs were obtained from the National Health Insurance Administration. The exchange rate of all costs was converted by 30 New Taiwan dollars per US dollar. Results: The introduced new coverage policy The annual drug cost of DAA-based therapy was 26.6 million US dollar and pegylated interferon /ribavirin was 9.9 million US dollar, respectively. Due to the high cure rate of the innovative new drug, this decreases the eligible patients for the treatment year by year. In 2019-2023, the health insurance fund for the hepatitis C treatment would be decreased by 15.45, 15.56, 15.63, 15.68, 15.72 million US dollar, respectively. Conclusions: Compared with pegylated interferon /ribavirin, the novel direct-acting antivirals (DAAs) is a relatively cheaper alternative with comparable clinical efficacy for HCV patients in Taiwan.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.